Compare Regeneron Pharmaceuticals Inc (REGN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Tapestry, Inc. trades at $114.76 (market cap $23.44B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.6× Tapestry, Inc.'s market cap, and Tapestry, Inc. pays the higher dividend (1.57%). Which is the better fit depends on your goals.
| REGN | TPR | |
|---|---|---|
Market Cap | $83.43B | $23.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $164.78 |
52-Week Low | $555.51 | $98.81 |
Enterprise Value | $78.14B | $26.25B |
Dividend Yield | 0.46% | 1.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TPR (Tapestry Inc.) is trading at $117.58, down 3.73% in the last session, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly. Recent earnings have consistently beaten estimates, and analyst consensus remains strongly bullish with a $182.44 price target representing 55% upside potential.
The outlook remains positive with international growth accelerating in China and Europe, supported by a direct-to-consumer model. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation. Institutional buying activity remains strong, with BlackRock acquiring a $2.6 billion position in Q2 2026, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
